Table 2.
Contributions of immunocytochemistry and FISH to the definitive diagnosis. ICC: Immunocytochemistry; LN: lymph node; LG-M: Low-grade malignant; HG-M: High-grade malignant.
| Cytopathology | Immunocytochemistry | FISH | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Milan System Category | Total Number of Cases | Total Number of Cases with ICC (%) | Did not Contribute to Diagnosis | Eliminated Metastasis of Secondary Tumours | Differentiated Benign/LG-M from HG-M | Provided the Diagnosis | Total Number of Cases with FISH (%) | Did not Contribute to Diagnosis | No Help (Negative) | Provided the Diagnosis | |
| Non-Diagnostic (ND) | Pauci-cellular | 55 | 2/55 (3.6%) | 1 (50%) | 1 (50%) | ||||||
| Cyst content | 25 | 3/25 (12%) | 1 (33.3%) | 1 (33.33%) | 1 (33.3%) | 1/25 (4%) | 1 (100%) | ||||
| Lymphocytes | 4 | 3/4 (75%) | 2 (66.7%) | 1 (33.3%) | |||||||
| Non-Neoplastic (NN) | Normal LN | 7 | 3/7 (42,9%) | 3 (100%) | |||||||
| Inflammation | 12 | 6/12 (50%) | 1 (16,7%) | 5 (83,3%) | |||||||
| Sialadenitis | 1 | 1/1 (100%) | 1 (100%) | ||||||||
| Cyst | 7 | 1/7 (14.3%) | 1 (100%) | ||||||||
| Atypia of undetermined significance (AUS) | 4 | 3/4 (75%) | 3 (100%) | 1/4 (25%) | 1 (100%) | ||||||
| Benign neoplasm (BN) | Pleomorphic adenoma | 89 | 12/89 (13.5%) | 2 (16.7%) | 9 (75%) | 1 (8.3%) | 32/89 (36%) | 7 (21.9%) | 14 (43.8%) | 11 (34.4%) | |
| Warthin’s tumour | 55 | 1/55 (1.8%) | 1 (100%) | 1/55 (1.82%) | 1 (100%) | ||||||
| Other | 1 | ||||||||||
| Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) | Oncocytic | 7 | 3/7 (42.9%) | 2 (66.7%) | 1 (33.3%) | 3/7 (42.9%) | 1 (33.3%) | 2 (66.7%) | |||
| Undetermined | 8 | 2/8 (25%) | 1 (50%) | 1 (50%) | 3/8 (37.5%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | |||
| Suspicious for malignancy (SM) | Epithelial | 6 | 3/6 (50%) | 3 (100%) | 3/6 (50%) | 2 (66.7%) | 1 (33.3%) | ||||
| Lymphoma | 10 | 7/10 (70%) | 2 (28.6%) | 2 (28.6%) | 1 (14.3%) | 2 (28.6%) | |||||
| Malignant (M) | Low-grade | 1 | 1/1 (100%) | 1 (100%) | 1/1 (100%) | 1 (100%) | |||||
| High-grade | 23 | 17/23 (73.9%) | 3 (17.6%) | 2 (11.8%) | 6 (35.3%) | 6 (35.3%) | 2/23 (8.7%) | 2 (100%) | |||
| Metastasis | 13 | 8/13 (61.5%) | 2 (25%) | 1 (12.5%) | 5 (62.5%) | ||||||
| Total | 328 | 76/328 (23,2%) | 21/76 (27.6%) | 9/76 (11.8%) | 28/76 (36.8%) | 18/76 (23.7%) | 48/328 (14.6%) | 10/48 (20.8%) | 22/48 (45.8%) | 16/48 (33.3%) | |